David Hale - Conatus Pharmaceuticals Insider

Conatus Pharmaceuticals Inc -- USA Stock  

USD 4.09  0.18  4.22%

Independent Chairman of the Board

Mr. David F. Hale is the Independent Chairman of the Board of Conatus Pharmaceuticals Inc. Since May 2006, he has served as Chairman CEO of Hale BioPharma Ventures. He was previously President and CEO of CancerVax Corporationrationration which merged with Micromet, Inc from October 2000 through May 2006, when he became Chairman of the combined companies. He is a serial entrepreneur who was involved in the founding andor development of a number of biotechnology and specialty pharmaceutical companies. After joining Hybritech, Inc., in 1982, he was President Chief Operating Officer and became CEO in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc. He was a cofounder and Chairman of Viagene, Inc. from 1987 to 1995. He was President and CEO of Women First HealthCare, Inc. from late 1997 to June 2000. Prior to joining Hybritech, he was Vice President and General Manager of BBL Microbiology Systems and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporationrationration, a division of Johnson Johnson, Inc. Mr. Hale is Chairman of Santarus, Inc and previously served as Chairman of Somaxon, Inc. prior to its acquisition in 2013. He also serves as Chairman of Colorescience, Inc., Ridge Diagnostics, Crisi, Inc., Intrepid Therapeutics, Neurelis, Inc., Agility Clinical, Advantar Laboratories, Inc. and Katama Pharmaceuticals, Inc. He also is a cofounder and serves on the Board of Directors of BIOCOM, is a former member of the Board of the Biotechnology Industry Organization, and the Biotechnology Institute. He also serves on the Board of Directors of the San Diego Economic Development Corporationrationration, and as Chairman of the Board of Trustees of Rady Childrens Hospital of San Diego. He is a cofounder of the CONNECT Program in Technology and Entrepreneurship
Age: 66  Chairman Since 2012      
858-376-2600  http://www.conatuspharma.com
Hale holds a B.A. in Biology and Chemistry from Jacksonville State University.

David Hale Latest Insider Activity

David Hale over three months ago via Macroaxis 
Purchase by David Hale of 400 shares of First US

Management Efficiency

The company has return on total asset (ROA) of (22.75) % which means that it has lost $22.75 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (74.5) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 12.97 M in liabilities with Debt to Equity (D/E) ratio of 41.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals Inc has Current Ratio of 2.64 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Conatus Pharmaceuticals Inc (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 25 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Idea Optimizer Now
   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Hide  View All  NextLaunch Idea Optimizer
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Conatus Pharmaceuticals Inc to your portfolio

Top Management

Conatus Pharmaceuticals Leadership Team
Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance

Conatus Pharmaceuticals Performance Indicators